Nothing Special   »   [go: up one dir, main page]

RU2016150377A - Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc - Google Patents

Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc Download PDF

Info

Publication number
RU2016150377A
RU2016150377A RU2016150377A RU2016150377A RU2016150377A RU 2016150377 A RU2016150377 A RU 2016150377A RU 2016150377 A RU2016150377 A RU 2016150377A RU 2016150377 A RU2016150377 A RU 2016150377A RU 2016150377 A RU2016150377 A RU 2016150377A
Authority
RU
Russia
Prior art keywords
antibody
paragraphs
compound according
compound
cancer
Prior art date
Application number
RU2016150377A
Other languages
English (en)
Other versions
RU2670157C2 (ru
RU2016150377A3 (ru
Inventor
Герардус Йозеф Андреас АРИАНС
Руди Герардус Элизабет КАУМАНС
Original Assignee
Синтон Байофармасьютикалс Б. В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016150377(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Синтон Байофармасьютикалс Б. В. filed Critical Синтон Байофармасьютикалс Б. В.
Publication of RU2016150377A publication Critical patent/RU2016150377A/ru
Publication of RU2016150377A3 publication Critical patent/RU2016150377A3/ru
Application granted granted Critical
Publication of RU2670157C2 publication Critical patent/RU2670157C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021Glutamate carboxypeptidase II (3.4.17.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (25)

1. Соединение конъюгат антитело-лекарственный препарат, в котором линкерный лекарственный препарат сайт-специфичным образом конъюгирован с антителом через встроенный цистеин в одной или более позициях указанного антитела, выбранных из 40, 41 и 89 тяжелой цепи (согласно нумерации Kabat); и 40 и 41 легкой цепи (согласно нумерации Kabat).
2. Соединение по п. 1, в котором указанный встроенный цистеин находится в одной или более позициях указанного антитела, выбранных из 40 и 41 тяжелой цепи и 40 и 41 легкой цепи в части Fab указанного антитела.
3. Соединение по п. 1 или 2, дополнительно содержащее встроенный цистеин в позиции 375 в части Fc указанного антитела (согласно нумерации Eu).
4. Соединение по любому из пп. 1-3, в котором указанный линкерный лекарственный препарат содержит производную дуокармицина.
5. Соединение конъюгат антитело-лекарственный препарат, в котором линкерный лекарственный препарат сайт-специфичным образом конъюгирован с антителом или связывающим антиген фрагментом антитела через встроенный цистеин в одной или более позициях указанного антитела, выбранных из 40, 41 и 89 тяжелой цепи (согласно нумерации Kabat); 152, 153, 155, 171, 247, 297, 339, 375 и 376 тяжелой цепи (согласно нумерации Eu); и 40, 41, 165 и 168 легкой цепи (согласно нумерации Kabat), при этом указанный линкерный лекарственный препарат содержит производную дуокармицина.
6. Соединение по любому из пп. 1-5 с формулой (I)
Figure 00000001
,
при этом n составляет 0-3, m представляет среднее DAR от 1 до 6, R1 выбирается из
Figure 00000002
,
y равно 1-16, и R2 выбирается из
Figure 00000003
.
7. Соединение по п. 6, в котором n составляет 0-1, m представляет среднее DAR от 1,5 до 2, R1 представляет собой
Figure 00000004
y равно 1-4, и R2 выбирается из
Figure 00000005
.
8. Соединение по любому из пп. 1-7 с формулой (II)
Figure 00000006
.
9. Соединение по любому из пп. 1-8, в котором указанное антитело связывается с антигеном-мишенью, который экспрессирован в или на клеточной мембране опухолевой клетки, и при этом указанное антитело поглощается клеткой после связывания с указанной целью.
10. Соединение по любому из пп. 1-9, в котором указанное антитело представляет собой антитело против аннексина A1, антитело против CD115, антитело против CD123, антитело против CLL-1, антитело против c-MET, антитело против MUC1, антитело против PSMA, антитело против 5T4 или антитело против TF.
11. Соединение по любому из пп. 1-10, в котором указанное антитело представляет собой моноклональное антитело против PSMA или моноклональное антитело против 5T4.
12. Соединение по п. 11, в котором указанный линкерный лекарственный препарат конъюгирован в позиции 41 вариабельной области тяжелой цепи указанного антитела против PSMA, предпочтительно, при этом тяжелая цепь указанного антитела против PSMA содержит последовательность аминокислот с SEQ ID, NO:2, и легкая цепь указанного антитела против PSMA содержит последовательность аминокислот с SEQ ID NO:5.
13. Соединение по п. 11, в котором указанный линкерный лекарственный препарат конъюгирован в позиции 41 вариабельной области тяжелой цепи указанного антитела против 5T4, предпочтительно, при этом тяжелая цепь указанного антитела против 5T4 содержит последовательность аминокислот с SEQ ID NO:8, и легкая цепь указанного антитела против 5T4 содержит последовательность аминокислот SEQ ID NO:11.
14. Фармацевтическая композиция, содержащая соединение по любому из пп. 1-13 и один или более фармацевтически приемлемых эксципиентов, предпочтительно, в форме лиофилизированного порошка.
15. Соединение по любому из пп. 1-13 или фармацевтическая композиция по п. 14 для применения в качестве медикамента.
16. Соединение по любому из пп. 1-13 или фармацевтическая композиция по п. 14 для применения в лечении человеческих солидных опухолей и гематологических злокачественных образований.
17. Соединение или фармацевтическая композиция по п. 16, при этом человеческие солидные опухоли выбираются из группы, состоящей из рака груди, рака желудка, рака ободочной и прямой кишки, рака уротелия, рака яичников, рака матки, рака легких, мезотелиомы, рака печени, рака поджелудочной железы и рака простаты.
RU2016150377A 2014-05-22 2015-05-22 Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc RU2670157C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169493.5 2014-05-22
EP14169493 2014-05-22
PCT/EP2015/061456 WO2015177360A1 (en) 2014-05-22 2015-05-22 Site-specific conjugation of linker drugs to antibodies and resulting adcs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018133015A Division RU2773536C2 (ru) 2014-05-22 2015-05-22 Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc

Publications (3)

Publication Number Publication Date
RU2016150377A true RU2016150377A (ru) 2018-06-25
RU2016150377A3 RU2016150377A3 (ru) 2018-06-25
RU2670157C2 RU2670157C2 (ru) 2018-10-18

Family

ID=50771151

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016150377A RU2670157C2 (ru) 2014-05-22 2015-05-22 Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc

Country Status (22)

Country Link
US (4) US10407743B2 (ru)
EP (3) EP3539544A1 (ru)
JP (2) JP6517240B2 (ru)
KR (1) KR102419766B1 (ru)
CN (1) CN106456794B (ru)
AU (2) AU2015261768B2 (ru)
CA (1) CA2947238A1 (ru)
CL (1) CL2016002941A1 (ru)
CY (1) CY1125232T1 (ru)
DK (1) DK3151865T3 (ru)
ES (1) ES2895623T3 (ru)
HR (1) HRP20211710T1 (ru)
HU (1) HUE056023T2 (ru)
LT (1) LT3151865T (ru)
MX (1) MX2016015176A (ru)
MY (1) MY183480A (ru)
PL (1) PL3151865T3 (ru)
PT (1) PT3151865T (ru)
RU (1) RU2670157C2 (ru)
SG (2) SG10201913977TA (ru)
WO (1) WO2015177360A1 (ru)
ZA (1) ZA201607109B (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
PL3108886T3 (pl) 2010-04-21 2021-01-11 Syntarga B.V. Koniugaty analogów cc-1065 i dwufunkcyjnych linkerów
PL2948183T3 (pl) 2014-01-10 2017-03-31 Synthon Biopharmaceuticals B.V. ADC duokarmycyny do zastosowania w leczeniu raka endometrium
ES2668984T3 (es) 2014-01-10 2018-05-23 Synthon Biopharmaceuticals B.V. CAF de duocarmicina para su uso en el tratamiento del cáncer de vejiga
HUE056023T2 (hu) * 2014-05-22 2022-01-28 Byondis Bv Kapcsolt drogok helyspecifikus konjugációja ellenanyagokhoz, és a kapott ADC-k
PT3152191T (pt) 2014-06-05 2019-08-30 Synthon Biopharmaceuticals Bv Processo melhorado para preparar profármacos de duocarmicina
DK3380122T3 (da) * 2015-11-24 2021-07-05 Byondis Bv Anti-5t4 antistoffer og antistoflægemiddel konjugater
US20210198377A1 (en) * 2015-12-24 2021-07-01 Xdcexplorer (Shanghai) Co., Ltd. Tpbg antibody and preparation method therefor, conjugate and use thereof
CN108883196A (zh) * 2016-02-05 2018-11-23 米伦纽姆医药公司 靶向gcc的抗体-药物缀合物
AU2017218615B2 (en) * 2016-02-12 2022-02-10 Byondis B.V. Selective reduction of cysteine-engineered antibodies
JP7179719B2 (ja) * 2016-06-06 2022-11-29 ポリセリックス・リミテッド 抗体、その使用及びそのコンジュゲート
CN108472371B (zh) * 2016-07-05 2022-05-24 江苏恒瑞医药股份有限公司 Egfr抗体-药物偶联物及其在医药上的应用
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
CA3038427A1 (en) 2016-10-11 2018-04-19 Synthon Biopharmaceuticals B.V. Non-linear self-immolative linkers and conjugates thereof
KR102614466B1 (ko) 2016-11-14 2023-12-14 비온디스 비.브이. 단일-보호된 알파, 오메가-디아미노 알칸의 제조 방법
CN118027200A (zh) * 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
CN108285487B (zh) * 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
JOP20190187A1 (ar) * 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
AU2018250336A1 (en) 2017-04-07 2019-09-26 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
US11696958B2 (en) * 2017-05-23 2023-07-11 Byondis B.V. Dual conjugation process for preparing antibody-drug conjugates
US20200129633A1 (en) * 2017-06-06 2020-04-30 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof
WO2018227018A1 (en) * 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof
US20200155702A1 (en) * 2017-06-16 2020-05-21 Eli Lilly And Company Engineered Antibody Compounds and Conjuates Thereof
JP2020532523A (ja) * 2017-09-02 2020-11-12 アッヴィ・インコーポレイテッド 抗egfr抗体薬物コンジュゲート(adc)及びその使用
JP2020534816A (ja) 2017-09-06 2020-12-03 エアウェイ・セラピューティクス・インコーポレイテッド サーファクタントタンパク質d(sp−d)を調製するための方法及び組成物
AU2018328113B2 (en) * 2017-09-06 2023-09-07 Airway Therapeutics, Inc. Methods, compositions and cells for preparing surfactant protein D (SP-D)
CA3083169A1 (en) 2017-11-24 2019-05-31 Vladimir Janousek Improved process for the synthesis of linker-drug vc-seco-duba
US11401345B2 (en) * 2017-11-27 2022-08-02 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
CN108187065B (zh) * 2017-12-29 2023-04-28 广东众生药业股份有限公司 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
SG11202008770QA (en) 2018-03-13 2020-10-29 Zymeworks Inc Anti-her2 biparatopic antibody-drug conjugates and methods of use
WO2019183438A1 (en) * 2018-03-23 2019-09-26 Seattle Genetics, Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
TWI841555B (zh) 2018-03-28 2024-05-11 日商田邊三菱製藥股份有限公司 cMET單株抗體結合劑的藥物接合物及其用途
AU2019272885A1 (en) 2018-05-25 2020-11-26 Alector Llc Anti-SIRPA antibodies and methods of use thereof
WO2020037024A1 (en) * 2018-08-16 2020-02-20 Genmab A/S Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
CN111655295B (zh) * 2018-08-29 2024-05-28 荣昌生物制药(烟台)股份有限公司 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途
WO2020092344A1 (en) * 2018-10-31 2020-05-07 Health Research, Inc. Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor
WO2020094561A1 (en) 2018-11-09 2020-05-14 Synthon Biopharmaceuticals B.V. Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
WO2020181846A1 (zh) * 2019-03-11 2020-09-17 凯惠科技发展(上海)有限公司 一种含半胱氨酸的抗体、药物偶联物及其应用
CA3154710A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
CA3165711A1 (en) 2020-02-06 2021-08-12 Johannes Henricus Matthias Schellens Combination containing a duocarmycin derivative-comprising antibody-drug conjugate and thiosulfate
WO2022008419A1 (en) 2020-07-06 2022-01-13 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
WO2022152308A1 (en) * 2021-01-18 2022-07-21 Wuxi Biologics (Shanghai) Co., Ltd. Engineered anti-trop2 antibody and antibody-drug conjugate thereof
CA3214718A1 (en) 2021-04-08 2022-10-13 Marion Blomenrohr Anti-c-met antibodies and antibody-drug conjugates
KR20240027761A (ko) 2021-06-28 2024-03-04 비온디스 비.브이. 인항원을 포함하는 접합체 및 요법에서의 이의 용도
CN114106180B (zh) * 2021-12-13 2023-07-28 中国药科大学 一种单克隆抗体及其应用
MX2024008269A (es) 2021-12-30 2024-09-18 Byondis Bv Enlazador-fármacos de antifolato y conjugados de anticuerpo-fármaco.
WO2023222580A1 (en) 2022-05-16 2023-11-23 Byondis B.V. Novel masked antibodies
WO2024027795A1 (zh) * 2022-08-04 2024-02-08 苏州开拓药业股份有限公司 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
WO2024133374A1 (en) 2022-12-22 2024-06-27 Byondis B.V. Novel linker drugs comprising phosphoantigens, novel conjugates and their use in therapy
CN116212045A (zh) * 2023-03-31 2023-06-06 温州医科大学 靶向癌细胞表面muc1的新型抗体药物偶联物及其制备方法与应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
ES2533695T3 (es) 2004-03-02 2015-04-14 Seattle Genetics, Inc. Anticuerpos cargados parcialmente y métodos para su conjugación
RU2007108716A (ru) 2004-09-10 2008-10-20 Вайет (Us) Гуманизированные антитела к антигену 5т4 и конъюгаты гуманизированного антитела к антигену 5т4 с калихеамицином
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
EP1912677B1 (en) 2005-06-20 2013-10-02 Psma Development Company, L.L.C. PSMA antibody-drug conjugates
NZ566982A (en) 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
US8044178B2 (en) 2006-03-10 2011-10-25 Wyeth Llc Anti-5T4 antibodies and uses thereof
MX2008015132A (es) * 2006-05-30 2008-12-10 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
ES2433379T3 (es) 2007-08-01 2013-12-10 Syntarga B.V. Análogos de CC-1065 sustituidos y sus conjugados
JP5677970B2 (ja) 2008-11-03 2015-02-25 シンタルガ・ビーブイ 新規cc−1065類似体およびその複合体
WO2011069019A2 (en) * 2009-12-02 2011-06-09 David Ho J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
PL3108886T3 (pl) * 2010-04-21 2021-01-11 Syntarga B.V. Koniugaty analogów cc-1065 i dwufunkcyjnych linkerów
JP5925875B2 (ja) * 2011-04-01 2016-05-25 ワイス・エルエルシー 抗体−薬剤コンジュゲート
EP3539982A3 (en) 2011-12-23 2020-01-15 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US10736903B2 (en) * 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
HUE054443T2 (hu) 2013-02-08 2021-09-28 Novartis Ag Ellenanyagok módosítására, ezáltal immunkonjugátumok elõállítására szolgáló specifikus helyek
ES2668984T3 (es) 2014-01-10 2018-05-23 Synthon Biopharmaceuticals B.V. CAF de duocarmicina para su uso en el tratamiento del cáncer de vejiga
WO2015104359A2 (en) 2014-01-10 2015-07-16 Synthon Biopharmaceuticals B.V. Method for purifying cys-linked antibody-drug conjugates
PL2948183T3 (pl) 2014-01-10 2017-03-31 Synthon Biopharmaceuticals B.V. ADC duokarmycyny do zastosowania w leczeniu raka endometrium
HUE056023T2 (hu) * 2014-05-22 2022-01-28 Byondis Bv Kapcsolt drogok helyspecifikus konjugációja ellenanyagokhoz, és a kapott ADC-k
PT3152191T (pt) 2014-06-05 2019-08-30 Synthon Biopharmaceuticals Bv Processo melhorado para preparar profármacos de duocarmicina
US20170320965A1 (en) 2014-09-22 2017-11-09 Synthon Biopharmaceuticals B.V. Pan-reactive antibodies to duocarmycins
DK3380122T3 (da) * 2015-11-24 2021-07-05 Byondis Bv Anti-5t4 antistoffer og antistoflægemiddel konjugater

Also Published As

Publication number Publication date
EP3539544A1 (en) 2019-09-18
LT3151865T (lt) 2021-10-25
SG10201913977TA (en) 2020-03-30
CN106456794B (zh) 2023-02-17
AU2020200175A1 (en) 2020-01-30
ES2895623T3 (es) 2022-02-22
AU2015261768A1 (en) 2016-11-03
PL3151865T3 (pl) 2022-01-03
HRP20211710T1 (hr) 2022-02-04
WO2015177360A1 (en) 2015-11-26
CA2947238A1 (en) 2015-11-26
EP3868379A1 (en) 2021-08-25
US11104968B2 (en) 2021-08-31
EP3151865B1 (en) 2021-09-01
CY1125232T1 (el) 2023-03-24
US20170080103A1 (en) 2017-03-23
RU2670157C2 (ru) 2018-10-18
KR102419766B1 (ko) 2022-07-13
SG11201609372UA (en) 2016-12-29
US20210388115A1 (en) 2021-12-16
US20190368000A1 (en) 2019-12-05
CN106456794A (zh) 2017-02-22
JP6900408B2 (ja) 2021-07-07
MX2016015176A (es) 2017-03-23
RU2018133015A (ru) 2018-12-04
JP6517240B2 (ja) 2019-05-22
AU2020200175B2 (en) 2021-08-19
CL2016002941A1 (es) 2017-12-22
PT3151865T (pt) 2021-11-17
BR112016026744A2 (pt) 2017-12-12
RU2016150377A3 (ru) 2018-06-25
KR20170005128A (ko) 2017-01-11
RU2018133015A3 (ru) 2021-12-07
US20190367999A1 (en) 2019-12-05
DK3151865T3 (da) 2021-10-25
JP2017524653A (ja) 2017-08-31
US10407743B2 (en) 2019-09-10
US11136633B2 (en) 2021-10-05
EP3151865A1 (en) 2017-04-12
HUE056023T2 (hu) 2022-01-28
MY183480A (en) 2021-02-19
ZA201607109B (en) 2018-05-30
JP2019089783A (ja) 2019-06-13
AU2015261768B2 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
RU2016150377A (ru) Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc
RU2013128444A (ru) Новые модуляторы и способы их применения
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
RU2016117810A (ru) Конъюгаты белок-полимер-лекарственное средство
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
JP2021502810A5 (ru)
RU2018122629A (ru) Антитела против 5t4 и конъюгаты антитело-лекарственное средство
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
RU2011145038A (ru) Несущие аматоксины мишень-связывающие молекулы для лечения рака
EA201391449A1 (ru) Антитела против пептидов цитозоля
RU2018100424A (ru) Комбинированная терапия для лечения злокачественной опухоли
HRP20180262T1 (hr) Monoklonska anti-gt468 protutijela za liječenje karcinoma
JP2019531084A5 (ru)
HRP20220133T1 (hr) Optimizirana anti-cd3 bispecifična antitijela i njihove upotrebe
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
MX2021014094A (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso.
RU2014138040A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2014138474A (ru) Новые модуляторы и способы применения
IL278574B1 (en) Compounds acting on glycans and methods of using them
JP2016521692A5 (ru)
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2010535713A5 (ru)
RU2014146951A (ru) Конъюгаты типа лиганд dr5-лекарственное средство
RU2019122802A (ru) Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы
JP2016519651A5 (ru)

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner